The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB

PLoS Comput Biol. 2016 Mar 11;12(3):e1004749. doi: 10.1371/journal.pcbi.1004749. eCollection 2016 Mar.

Abstract

Treatment failure after therapy of pulmonary tuberculosis (TB) infections is an important challenge, especially when it coincides with de novo emergence of multi-drug-resistant TB (MDR-TB). We seek to explore possible causes why MDR-TB has been found to occur much more often in patients with a history of previous treatment. We develop a mathematical model of the replication of Mycobacterium tuberculosis within a patient reflecting the compartments of macrophages, granulomas, and open cavities as well as parameterizing the effects of drugs on the pathogen dynamics in these compartments. We use this model to study the influence of patient adherence to therapy and of common retreatment regimens on treatment outcome. As expected, the simulations show that treatment success increases with increasing adherence. However, treatment occasionally fails even under perfect adherence due to interpatient variability in pharmacological parameters. The risk of generating MDR de novo is highest between 40% and 80% adherence. Importantly, our simulations highlight the double-edged effect of retreatment: On the one hand, the recommended retreatment regimen increases the overall success rate compared to re-treating with the initial regimen. On the other hand, it increases the probability to accumulate more resistant genotypes. We conclude that treatment adherence is a key factor for a positive outcome, and that screening for resistant strains is advisable after treatment failure or relapse.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / administration & dosage*
  • Computer Simulation
  • Humans
  • Medication Adherence / statistics & numerical data*
  • Models, Biological*
  • Models, Statistical
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / physiology*
  • Risk Assessment / methods
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / microbiology*
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antitubercular Agents

Grants and funding

This work was supported by the department of the authors, the Swiss National Science Foundation grant PBEZP3_140163 and the German Academic Exchange Service grant D/11/45747 to PAzW, the Swiss National Science Foundation grant PZ00P3-142411 to RK and the European Research Council under the 7th Framework Programme of the European Commission (PBDR: Grant Agreement Number 268540) to SB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.